Showing results (41-50 of 85) with videos related to
Sort By:
Pageof 9
ACS Chemical Biology|June 11, 2014
A small-molecule targeting the microRNA binding domain of argonaute 2 improves the retinoic acid differentiation response of the acute promyelocytic leukemia cell line NB4Silvia Masciarelli, Roberto Quaranta, Ilaria Iosue, et al.Current Topics in Medicinal Chemistry|November 1, 2013
Nicotinamide phosphoribosyltransferase as a target in inflammation- related disordersFabrizio Montecucco, Michele Cea, Antonia Cagnetta, et al.Biochemistry|August 8, 2019
Unveiling the Biochemistry of the Epigenetic Regulator SMYD3Edoardo Fabini, Vladimir O Talibov, Filip Mihalic, et al.Cadernos De Saude Publica|July 16, 2002
[National pharmaceutical policy in Colombia and social security reform: access and rational use of medicines]Samuel Mejia Restrepo, Alba Lucía Velez Arango, Olga Clemencia Buritica Arboleda, et al.Scientific Reports|May 7, 2026
Structure-guided identification of small molecules potentially able to modulate GDF15 activityAntonio Chiariello, Lorenzo Lenti, Lorenzo Trofarello, et al.Regulatory Toxicology and Pharmacology : RTP|May 30, 2023
A non-clinical and clinical IUCLID database for 530 pharmaceuticals (part I): Methodological aspects of its developmentMartina Evangelisti, Marco Daniele Parenti, Greta Varchi, et al.Toxicological Sciences : an Official Journal of the Society of Toxicology|October 23, 2021
An Afucosylated Anti-CD32b Monoclonal Antibody Induced Platelet-Mediated Adverse Events in a Human Fcγ Receptor Transgenic Mouse Model and Its Potential Human TranslatabilityBabette Wolf, Valentina Jeliazkova-Mecheva, Alberto Del Rio-Espinola, et al.Journal of Computer-Aided Molecular Design|March 23, 2010
A computational workflow for the design of irreversible inhibitors of protein kinasesAlberto Del Rio, Miriam Sgobba, Marco Daniele Parenti, et al.Journal of Chemical Information and Modeling|June 1, 2012
Comparative analysis of pharmacophore screening toolsMarijn P A Sanders, Arménio J M Barbosa, Barbara Zarzycka, et al.Current Pharmaceutical Design|September 29, 2012
Immunoproteasome in cancer and neuropathologies: a new therapeutic target?Elena Bellavista, Federico Andreoli, Marco Daniele Parenti, et al.Pageof 9